Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results

PRINCETON, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported operational highlights and financial results for the fiscal quarter ended December 31, 2008.

Financial Results

Revenues were $0.5 million during each of the quarters ended December 31, 2008 and December 31, 2007 and reflect amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities was $15.3 million for the quarter ended December 31, 2008 as compared to $17.1 million for the quarter ended December 31, 2007. Pharmasset held $51.8 million in cash and cash equivalents and short term investments at the end of the fiscal first quarter.

Total costs and expenses for the quarter ended December 31, 2008 were $18.1 million as compared to $13.2 million for the same period in 2007. The increased operating expenses for the quarter ended December 31, 2008 were primarily the result of an increase in phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B (HBV) infection, as well as increased preclinical development expenses for our second generation HCV product candidate, PSI-7851.

Pharmasset reported a net loss attributable to common stockholders of $18.3 million, or $0.78 per share for the quarter ended December 31, 2008, as compared to a net loss attributable to common stockholders of $12.2 million, or $0.57 per share for the quarter ended December 31, 2007.

Recent Highlights:

-- In November 2008, Roche initiated the INFORM-1 trial, a potentially ground-breaking study to investigate the activity of a combination of two oral antiviral molecules to treat hepatitis C virus (HCV) in the absence of interferon. The study will investigate the combination of Pharmasset's R7128 with InterMune's R7227, a protease inhibitor;

-- On January 11, 2009, Pharmasset announced that the company and its development partner, Roche, had agreed with the FDA on the design for a phase 2b trial with R7128, a nucleoside inhibitor of HCV, slated to initiate in the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset filed an IND for PSI-7851, a nucleotide inhibitor of HCV, with the FDA and expects to initiate a Phase 1 clinical trial to study safety and pharmacokinetics in healthy volunteers at the end of the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset and Bukwang Pharm. Co., Ltd. entered into an amendment of their license agreement covering clevudine. The amendment expands the territories in which Pharmasset has been granted rights to include Australia, Japan, New Zealand and Taiwan;

-- On February 5, 2009, Pharmasset completed a registered direct offering that raised net proceeds of $43.5 million.

"We had a very productive start to 2009, filing an IND for PSI-7851, our second generation nucleotide for HCV and, strengthening our balance sheet by raising $43.5 million in a tough financial market" stated Schaefer Price, President and Chief Executive Officer. "Our goal remains to build a leading franchise of nucleoside inhibitors for hepatitis C and B. Our plan is to provide updates throughout the year on all of our programs, including the first antiviral data on PSI-7851 in the second half of 2009."

Calendar Year 2009 Anticipated Milestones:

-- Roche initiates phase 2b study of R7128 in first quarter of 2009;

-- Complete enrollment of clevudine registration trials at end of first quarter of 2009;

-- Initiate Phase 1 studies with PSI-7851 in the first quarter of 2009;

-- Report interim results from INFORM-1 trial in second quarter of 2009;

-- Report interim results from 28 day add-on study with R7128 in non-responder, HCV genotype 2 and genotype 3 patients in first half of 2009;

-- Report interim results from 28 day add-on study with R7128 in treatment naive, HCV genotype 1 patients in first half of 2009;

-- Report phase 1 antiviral data with PSI-7851 in second half of 2009.

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe, among other countries. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. Pharmasset also anticipates initiating phase 1 studies with its second generation nucleotide inhibitor for HCV, PSI-7851 in the first quarter of 2009.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation,, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended December 31, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

                            PHARMASSET, INC.

                                               Three Months Ended
                                                  December 31,
                                               2008          2007
                                               ----          ----

    REVENUES                                 $464,291      $464,291
                                             --------      --------

      Research and development             14,022,930    10,550,371
      General and administrative            4,069,370     2,619,745
                                            ---------     ---------

        Total costs and expenses           18,092,300    13,170,116
                                           ----------    ----------

    OPERATING LOSS                        (17,628,009)  (12,705,825)

    INVESTMENT INCOME                         109,524       896,402
    INTEREST EXPENSE                         (756,912)     (363,176)
                                             --------      --------

    LOSS BEFORE INCOME TAXES              (18,275,397)  (12,172,599)
    PROVISION FOR INCOME TAXES                      -             -
                                                  ---           ---

    NET LOSS                             $(18,275,397) $(12,172,599)
                                         ============  ============

    NET LOSS                             $(18,275,397) $(12,172,599)
    AVAILABLE-FOR-SALE INVESTMENTS              1,089             -
                                                -----           ---
    COMPREHENSIVE NET LOSS               $(18,274,308) $(12,172,599)
                                         ============  ============

      BASIC                                    $(0.78)       $(0.57)
      DILUTED                                  $(0.78)       $(0.57)

      BASIC                                23,369,487    21,263,668
      DILUTED                              23,369,487    21,263,668

                               PHARMASSET, INC.
                           CONDENSED BALANCE SHEET

                                                 As of
                                              December 31,       As of
                                                  2008        September 30,
                                              (unaudited)        2008
                                              -----------        ----
      Cash and cash equivalents               $51,315,887    $63,073,103
      Short-term investments                      498,467        497,310
      Amounts due from collaboration partner      906,072      1,169,690
      Prepaid expenses and other assets           641,465      1,008,083
                                                  -------      ---------
        Total current assets                   53,361,891     65,748,186
                                               ----------     ----------

      Laboratory, office furniture
       and equipment                            3,541,633      3,362,846
      Leasehold improvements                    1,836,553      1,836,553
                                                ---------      ---------
                                                5,378,186      5,199,399
      Less accumulated depreciation
       and amortization                        (2,681,396)    (2,432,325)
                                               ----------     ----------
        Total equipment and leasehold
         improvements, net                      2,696,790      2,767,074
    OTHER ASSETS                                  456,377        466,809
                                                  -------        -------
    TOTAL                                     $56,515,058    $68,982,069
                                              ===========    ===========

      Current portion of long-term debt        $4,474,131     $2,651,592
      Current portion of capital
       lease obligation                                 -         41,641
      Accounts payable                          3,708,060      2,466,052
      Accrued expenses                          6,060,141      6,182,417
      Deferred rent                               124,462        124,463
      Deferred revenue                          1,857,136      1,857,136
                                                ---------      ---------
        Total current liabilities              16,223,930     13,323,301

    DEFERRED RENT                                  48,421         79,793
    DEFERRED REVENUE                            3,404,674      3,868,965
    LONG-TERM DEBT, net                        18,053,545     16,522,665
                                               ----------     ----------
        Total liabilities                      37,730,570     33,794,724
                                               ----------     ----------


    Common Stock, $0.001 par value,
     100,000,000 shares authorized,
     23,390,862 and 23,340,498 shares
     issued and outstanding at
     December 31, 2008 (unaudited) and
     September 30, 2008, respectively              23,391         23,340
    Warrants to purchase 127,248 and
     116,183 shares of common stock
     for $12.05 per share, as of
     December 31, 2008, (unaudited) and
     September 30, 2008, respectively           1,229,767      1,140,114
    Additional paid-in capital                147,600,186    145,818,439
    Accumulated other comprehensive
     (loss) income                                 (1,515)        (2,604)
    Accumulated deficit                      (130,067,341)  (111,791,944)
                                             ------------   ------------
        Total stockholders' equity             18,784,488     35,187,345
                                               ----------     ----------
    TOTAL                                     $56,515,058    $68,982,069
                                              ===========    ===========

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of ... Israel time, at the law offices of Goldfarb ... Floor, Tel Aviv, Israel . ... Tamir to the Board of Directors; , election of ... of an amendment to certain terms of options granted to our Chief ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
Breaking Biology News(10 mins):